The Week in Review: Burrill and Infinity Announce China Life Science Fund

Burrill and Infinity will co-invest in China life science companies; George Soros committed $40 million to Sihuan Pharma’s upcoming Hong Kong IPO; Pfizer’s new Wuhan R&D center, focused on radiation biology, is up and running; Roche’s Tarceva proved to be very effective against a specific form of lung cancer in a China trial; Vital Therapies said its bioartifical liver support system produced a significant increase in transplant-free survival; OrbusNeich completed enrollment in a 180-patient trial of its bio-engineered stent at 11 China sites; and MingSight Pharma bought the worldwide rights to two Pfizer early stage molecules for ophthalmic disorders. More details…. Stock Symbols: (HK: 0460) (NYSE: PFE) (VX: ROG)